

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**VOLUNTARY ANNOUNCEMENT**

**INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

The board of directors of the Company (the “**Board**”) wishes to announce that it has an intention to exercise its powers under the general mandate (the “**Share Repurchase Mandate**”) given to the Board pursuant to the resolutions of the shareholders of the Company (the “**Shareholders**”) passed at the annual general meeting of the Company (the “**AGM**”) held on June 9, 2023, to repurchase up to 45,759,198 shares of the Company (the “**Shares**”), being 10% of the total number of the issued Shares as at the date of the AGM (the “**Proposed Share Repurchase**”), with such mandate to expire upon whichever is the earliest of: (a) the conclusion of the next annual general meeting of the Company; or (b) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the articles of association of the Company to be held; or (c) the revocation or variation of the authority given under the ordinary resolution approving the Share Repurchase Mandate by an ordinary resolution of the Shareholders in general meeting.

On July 14, 2023, with due consideration to the Company’s remarkable advancements in commercialization, as well as its enhanced profitability and improved cash flow, the Board has decided to utilize the Share Repurchase Mandate and, subject to market conditions, repurchase Shares in the open market from time to time to use up to HK\$500 million in funds for the Proposed Share Repurchase. The Company intends to finance the Proposed Share Repurchase by its own financial resources other than the proceeds from the listing of the shares on the Main Board of The Stock Exchange of Hong Kong Limited and the proceeds raised from the top-up placing in January 2023.

The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Board will continue to monitor the market conditions and will repurchase Shares in the open market at appropriate times in the near future in accordance with the requirements under Rule 10.06 of the Listing Rules.

The Board believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

**As at the date of this announcement, the Company has not repurchased any Shares. Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, July 14, 2023

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU and Dr. Donald Kwok Tung LI as independent non-executive Directors.*